Modern therapeutic approaches in Parkinson's disease

Expert Reviews in Molecular Medicine

Volumn 5, Issue 10, 2003, Pages 1-20

  Lewis, Simon J G ^a   Caldwell, Maeve A ^a   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

synuclein; cell transplantation; neurodegeneration; neuroprotection; novel drugs; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; NEUROPROTECTIVE AGENT;

FETAL TISSUE TRANSPLANTATION; HUMAN; PARKINSON DISEASE; REVIEW; STEM CELL TRANSPLANTATION;

ANTIPARKINSON AGENTS; FETAL TISSUE TRANSPLANTATION; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; STEM CELL TRANSPLANTATION;

EID: 31044454889     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399403006008     Document Type: Review

References (140)

1. Parkinson, J. (1817) An Essay on the Shaking Palsy, Sherwood, London
2. Jellinger , K. (1987) The pathology of parkinsonism. In Movement Disorders 2 (Marsden, C.D. and Fahn, S., eds), pp. 124-165, Butterworth- Heinemann
3. Kish, S.J., Shannak, K. and Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318, 876-880, PubMed: 88174904 (Pubitemid 18090271)
4. Bernheimer, H. et al. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20, 415-455, PubMed: 74081469
5. Morrish, P.K., Sawle, G.V. and Brooks, D.J. (1996) Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 119, 2097-2103, PubMed: 97163178
6. Brooks, D.J. et al. (1990) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113, 1539-1552, PubMed: 91059189 (Pubitemid 20385930)
7. Cotzias, G.C., Van Woert, M.H. and Schiffer, L.M. (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276, 374-379, PubMed: 67087242
8. Foltynie, T. et al. (2002) The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry 73, 363-370, PubMed: 22220445
9. Checkoway, H. and Nelson, L.M. (1999) Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10, 327-336, PubMed: 99245877 (Pubitemid 29187771)
10. Marsden, C.D. and Parkes, J.D. (1976) Effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1, 292-296, PubMed: 76124463
11. Rascol, O. et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342, 1484-1491, PubMed: 20256707
12. Hauser , R.A. and Olano,w C.W. (1993) Oorbuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 8, 512-514, PubMed: 94049872 (Pubitemid 23291208)
13. Olanow, C.W. et al. (1994) A multicenter doubleblind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 9, 40-47, PubMed: 94187781 (Pubitemid 24022613)
14. Lhermitte, F., Agid, Y. and Signoret, J.L. (1978) Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol 35, 261-263, PubMed: 78165304 (Pubitemid 8311538)
15. Langston, J.W. et al. (1983) Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science 219, 979-980, PubMed: 83119954 (Pubitemid 13189531)
16. Mytilineou, C. and Cohen, G. (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 45, 1951-1953, PubMed: 86036278 (Pubitemid 16204326)
17. Ebadi, M. et al. (2002) Neuroprotective actions of selegiline. J Neurosci Res 67, 285-289, PubMed: 21671520 (Pubitemid 34137134)
18. Shoulson, I. (1998) DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 44, S160-166, PubMed: 98420018
19. Tatton, N.A. et al. (1998) A fluorescent doublelabeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44, S142-148, PubMed: 98420015 (Pubitemid 28423841)
20. Olanow, C.W., Jenner, P. and Brooks, D. (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44, S167-174, PubMed: 98420019 (Pubitemid 28423845)
21. Turski, L. et al. (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-Daspartate antagonists. Nature 349, 414-418, PubMed: 91125457 (Pubitemid 21926101)
22. Barneoud, P. et al. (1996) Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 74, 971-983, PubMed: 97051127 (Pubitemid 26313341)
23. Boireau, A. et al. (1994) Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 5, 2657-2660, PubMed: 95210653
24. Carvey, P.M, Pieri, S. and Ling, Z.D. (1997) Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 104, 209-228, PubMed: 97346666 (Pubitemid 27196476)
25. Sawada, H. et al. (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 44, 110-119, PubMed: 98330172 (Pubitemid 28323660)
26. Gassen, M., Gross, A. and Youdim, M.B. (1998) Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 13, 661-667, PubMed: 98349560 (Pubitemid 28334099)
27. Nishibayashi, S. et al. (1996) Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 67, 2208-2211, PubMed: 97016920 (Pubitemid 26349701)
28. Whone, A.L. et al. (2002) The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-Dopa. Neurology 58, A82-83 (American Academy of Neurology Annual Meeting)
29. Levy, R. et al. (2001) Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. Brain 124, 2105-2118, PubMed: 21455228 (Pubitemid 32945907)
30. Hutchison, W.D. et al. (1994) Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. Neuroreport 5, 1533-1537, PubMed: 95035978 (Pubitemid 24251890)
31. Bradford, H.F. et al. (1999) Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease. Adv Neurol 80, 19-25, PubMed: 99338887
32. Hur elbrink, C.B. and Bark,e rR.A. (0201) Prospects for the treatment of Parkinson's disease using neurotrophic factors. Expert Opin Pharmacother 2, 1531-1543, PubMed: 21683346 (Pubitemid 33019724)
33. Kordower, J.H. et al. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46, 419-424, PubMed: 99410002 (Pubitemid 29416283)
34. Kordower, J.H. et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773, PubMed: 20508095
35. Gill, S. et al. (2002) Intraparenchymal putaminal administration of glial derived neurotrophic factor in the treatment of advanced Parkinson's disease. Neurology 58, A241 (American Academy of Neurology Annual Meeting)
36. Alexander, G.E., DeLong, M.R. and Strick, P.L. (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9, 357-381, PubMed: 86213671 (Pubitemid 16055790)
37. Mitchell, I.J. et al. (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32, 213-226, PubMed: 90067029 (Pubitemid 19284718)
38. Bergman, H. et al. (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72, 507-520, PubMed: 95074659 (Pubitemid 24273560)
39. Playford, E.D. et al. (1992) Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 32, 151-161, PubMed: 92378132
40. Jahanshahi, M. et al. (1995) Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movementrelated potentials in normal and Parkinson's disease subjects. Brain 118, 913-933, PubMed: 95384630
41. Jenkins, I.H. et al. (1992) Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32, 749-757, PubMed: 93111699
42. Hamada, I. and DeLong, M.R. (19)9 2Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding. J Neurophysiol 68, 1859-1866, PubMed: 93124179
43. Hamada, I. and DeLong, M.R. (1992) Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 68, 1850-1858, PubMed: 93124178
44. Matsumura, M. et al. (1995) Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 65, 59-70, PubMed: 95272932
45. Kato, M. and Kimura, M. (1992) Effects of reversible blockade of basal ganglia on a voluntary arm movement. J Neurophysiol 68, 1516-1534, PubMed: 93124153
46. Burbaud, P. et al. (1998) Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey. Brain Res 780, 102-107, PubMed: 98156817 (Pubitemid 28068085)
47. Merello, M. et al. (1999) Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Mov Disord 14, 45-49, PubMed: 99114902 (Pubitemid 29224675)
48. Hutchinson, W.D. et al. (1997) Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 42, 767-775, PubMed: 98052469
49. Lozano, A.M. et al. (2000) Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 47, S141-146, PubMed: 20222795 (Pubitemid 30192019)
50. Vila, M. et al. (1997) Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J Neurosci 17, 765-773, PubMed: 98007485 (Pubitemid 27024588)
51. Herrero, M.T. et al. (1996) Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 47, 219-224, PubMed: 96291044
52. Parkinson Study Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345, 956-963, PubMed: 21442324
53. Olanow, C.W. and Obeso, J.A. (2000) Preventing levodopa-induced dyskinesias. Ann Neurol 47, S167-176; discussion S176-168, PubMed: 20222799
54. Lee, T. et al. (1978) Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273, 59-61, PubMed: 79010571 (Pubitemid 8312147)
55. Cortes, R. et al. (1989) Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 483, 30-38, PubMed: 89208221 (Pubitemid 19082435)
56. Chase, T.N. et al. (1989) Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39, 7-10; discussion 19, PubMed: 90067077 (Pubitemid 20020575)
57. Obeso, J.A. et al. (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 6, 889-897, PubMed: 95039994 (Pubitemid 24185313)
58. Pearce, R.K. et al. (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13, 234-241, PubMed: 98198741 (Pubitemid 28127797)
59. Mouradian, M.M. et al. (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 27, 18-23, PubMed: 90146188 (Pubitemid 20031354)
60. Vaamonde, J., Luquin, M.R. and Obeso, J.A. (1990) Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. Mov Disord 5, 260-262, PubMed: 90356044 (Pubitemid 20311781)
61. Oertel, W.H. (2000) Pergolide vs L-dopa (PELMOPET). Mov Disord 15 (Suppl 3), S4
62. Shoulson, I. (2000) Pramipexole versus levodopa in early Parkinson's disease: the randomised controlled CALM-PD trial. Mov Disord 15 (Suppl 3), S4
63. Rinne, U.K. et al. (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55, 23-30, PubMed: 98144161 (Pubitemid 28051035)
64. Sage, J.I. et al. (1988) Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24, 87-89, PubMed: 88325302
65. Block, G. et al. (1997) Comparison of immediaterelease and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 37, 23-27, PubMed: 97170724 (Pubitemid 27037728)
66. Parkinson Study Group 1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 42, 747-755, PubMed: 98052467
67. Olanow, C.W. and Obeso, J.A. (2000) Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 55, S72-77; discussion S78-81, PubMed: 21023050
68. Rabey, J.M. et al. (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23, 324-330, PubMed: 21459687 (Pubitemid 32047014)
69. Morrish, P.K., Sawle, G.V. and Brooks, D.J. (1995) Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59, 597-600, PubMed: 96103126
70. Zeng, B.Y. et al. (2000) Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12, 1096-1104, PubMed: 20226265
71. Quinn, N. et al. (1986) Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1, 65-68, PubMed: 89056940
72. Gerfen, C.R. et al. (1990) D1 and dDo2pamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432, PubMed: 91075237 (Pubitemid 120031867)
73. Young, W.S., 3rd, Bonner, T.I. and Brann, M.R. (1986) Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA 83, 9827-9831, PubMed: 87092341 (Pubitemid 17223450)
74. Piccini, P., Weeks, R.A. and Brooks, D.J. (1997) Alterations in opioid receptor binding in Parkinson's disease patients with levodopainduced dyskinesias. Ann Neurol 42, 720-726, PubMed: 98052464 (Pubitemid 27481544)
75. Engber, T.M. et al. (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 552, 113-118, PubMed: 92004751
76. Herrero, M.T. et al. (1995) Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68, 1189-1198, PubMed: 96100502
77. Menegoz, M. et al. (1995) Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 7, 125-128, PubMed: 96352175 (Pubitemid 26077212)
78. Oh, J.D. et al. (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 813, 150-159, PubMed: 99043811 (Pubitemid 29012528)
79. Oh, J.D., Vaughan, C.L. and Chase, T.N. (1999) Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 821, 433-442, PubMed: 99165647 (Pubitemid 29222808)
80. Khan, S.M., Smith, T.S. and Bennett, J.P., Jr. (1999) Effects of single and multiple treatments with Ldihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions. J Neurosci Res 55, 71-79, PubMed: 99105441 (Pubitemid 29014412)
81. Cenci, M.A. et al. (1999) Changes in the regional and compartmental distribution of FosB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94, 515-527, PubMed: 20043814 (Pubitemid 29436078)
82. Cenci, M.A., Lee, C.S. and BjorklunAd,. (1998) LDOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphinand glutamic acid decarboxylase mRNA. Eur J Neurosci 10, 2694-2706, PubMed: 99145682 (Pubitemid 28362576)
83. Papa, S.M. and Chase, T.N. (1996) Levodopainduced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39, 574-578, PubMed: 96202568
84. Verhagen Metman, L. et al. (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50, 1323-1326, PubMed: 98255420 (Pubitemid 28240346)
85. Verhagen Metman, L. et al. (1998) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51, 203-206, PubMed: 98337560 (Pubitemid 28345384)
86. Trabucchi, M., Bassi, S. and Frattola, L. (1982) Effect of naloxone on the "on-off' syndrome in patients receiving long-term levodopa therapy. Arch Neurol 39, 120-121, PubMed: 82134485 (Pubitemid 12222033)
87. Sandyk, R. and Snider, S.R. (1986) Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease. Am J Psychiatry 143, 118, PubMed: 86100893
88. Nutt, J.G. et al. (1978) Effect of an opiate antagonist on movement disorders. Arch Neurol 35, 810-811, PubMed: 79061516 (Pubitemid 9021887)
89. Rascol, O. et al. (1994) Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 9, 437-440, PubMed: 95059108 (Pubitemid 24238372)
90. Kanda, T. et al. (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43, 507-513, PubMed: 98206409 (Pubitemid 28231727)
91. Grondin, R. et al. (2000) Noradrenoceptor antagonism with idazoxan improves L-dopainduced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361, 181-186, PubMed: 20148310 (Pubitemid 30062450)
92. Dray , A. et al. (1978) The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res 151, 431-442, PubMed: 78212342 (Pubitemid 8393857)
93. Kleedorfer, B., Lees, A.J. and Stern, G.M. (1991) Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 54, 376-377, PubMed: 91277737
94. Hammerstad, J.P. et al. (1986) Buspirone in Parkinson's disease. Clin Neuropharmacol 9, 556-560, PubMed: 87102692 (Pubitemid 17217326)
95. Barker, R.A. and Dunnett, S.B. (1999) Neural Repair, Transplantation and Rehabilitation, Psychology Press, Hove, UK
96. Freeman, T.B. and Widner, H., eds (1998) Cell Transplantation for Neurological Disorders: toward Reconstruction of the Human Central Nervous System, Humana Press, NJ, USA
97. Kordower, J.H. et al. (1995) Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical, and neurochemical analysis. Cell Transplant 4, 155-171, PubMed: 95291614
98. Kordower, J.H. et al. (1996) Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 370, 203-230, PubMed: 96404549 (Pubitemid 26227146)
99. Olanow, C.W., Kordower, J.H. and Freeman, T.B. (1996) Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19, 102-109, PubMed: 97076896 (Pubitemid 26059233)
100. Lindvall, O. (1997) Neural transplantation: a hope for patients with Parkinson's disease. Neuroreport 8, iii-x, PubMed: 97472955
101. Piccini, P. et al. (2000) Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 48, 689-695, PubMed: 20529915
102. Piccini, P. et al. (1999) Dopamineel erase from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2, 1137-1140, PubMed: 20040725 (Pubitemid 30126374)
103. Kordower, J.H., Freeman, T.B. and Olanow, C.W. (1998) Neuropathology of fetal nigral grafts in patients with Parkinson's disease. Mov Disord 13, 88-95, PubMed: 98273780
104. Freed, C.R. et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344, 710-719, PubMed: 21115004 (Pubitemid 32204988)
105. Hagell, P. et al. (2002) Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5, 627-628, PubMed: 22079963 (Pubitemid 34742975)
106. Widner, H. (1998) The Lund transplant program for Parkinson's disease and patients with MPTPinduced parkinsonism. In Cell Transplantation for Neurological disorders: toward Reconstruction of the Human Central Nervous System (Freeman, T.B. and Widner, H., eds), pp. 1-17, Humana Press, NJ, USA
107. Barker, R.A. (2000) Porcine neural xenografts: what are the issues? Novartis Found Symp 231, 184-196, PubMed: 21014496
108. Barker, R.A., Kendall, A.L. and Widner, H. (2000) Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project. Cell Transplant 9, 235-246, PubMed: 20269533 (Pubitemid 30252689)
109. Schumacher, J.M. et al. (2000) Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54, 1042-1050, PubMed: 20183214 (Pubitemid 30151843)
110. Deacon, T. et al. (1997) Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 3, 350-353, PubMed: 97208925 (Pubitemid 27112937)
111. Hauser, R.A., Watts, R. and Freeman, T.B. (2001) A double-blind, randomised, controlled, multicenter clinical trial of the safety and efficacy of transplanted fetal porcine ventral mesencephalic cells versus imitation surgery in patients with Parkinson's disease. Mov Disord 16, 3-4
112. Gage, F.H. (2000) Mammalian neural stem cells. Science 287, 1433-1438, PubMed: 20156755 (Pubitemid 30127128)
113. McKay, R. (2000) Stem cells and the cellular organization of the brain. J Neurosci Res 59, 298-300, PubMed: 20145989 (Pubitemid 30107968)
114. Paul, G., Li, J.Y. and Brundin, P. (2002) Stem cells: hype or hope? Drug Discov Today 7, 295-302 (Pubitemid 34195423)
115. Weissman, I.L. (2002) Stem cells-scientific, medical, and political issues. N Engl J Med 346, 1576-1579, PubMed: 22010370 (Pubitemid 34755700)
116. Rosser, A. (2000) Stem cell research-will further work be permitted? Neuroreport 11, A15, PubMed: 21033193
117. Paalman, M.H. (2001) Stem cells and cloning: The fuss, revisited. Anat Rec 265, 121-122, PubMed: 21349667
118. Gensburger, C., Labourdette, G. and Sensenbrenner, M. (1987) Brain basic fibroblast growth factor stimulates the proliferation of rat neuronal precursor cells in vitro. FEBS Lett 217, 1-5, PubMed: 87247186 (Pubitemid 17093537)
119. Reynolds, B.A., Tetzlaff, W. and Weiss, S. (1992) A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 12, 4565-4574, PubMed: 93057807
120. Svendsen, C.N. et al. (1998) A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 85, 141-152, PubMed: 99089546 (Pubitemid 29003064)
121. Vescovi, A.L. et al. (1999) Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol 156, 71-83, PubMed: 99210427 (Pubitemid 29152984)
122. Carpenter, M.K. et al. (1999) In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol 158, 265-278, PubMed: 99346111 (Pubitemid 29382819)
123. Quinn, S.M. et al. (1999) Lineage restriction of neuroepithelial precursor cells from fetal human spinal cord. J Neurosci Res 57, 590-602, PubMed: 99393592 (Pubitemid 29411474)
124. Caldwell, M.A. et al. (2001) Growth factors regulate the survival and fate of cells derived from human neurospheres. Nat Biotechnol 19, 475-479, PubMed: 21227158 (Pubitemid 32428293)
125. Ling, Z.-D. et al. (1997) Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp Neurol 149, 411-423
126. Takahashi, J, Palmer, T.D. and Gage, F.H. (1999) Retinoic acid and neurotrophins collaborate to regulate neurogenesis in adult-derived neural stem cell cultures. J Neurobiol 38, 65-81, PubMed: 99149809 (Pubitemid 29016815)
127. Sanchez-Pernaute, R. et al. (2001) In vitro generation and transplantation of precursorderived human dopamine neurons. J Neurosci Res 65, 284-288, PubMed: 21385481 (Pubitemid 32727029)
128. Stull, N.D., Jung, J.W. and Iacovitti, L. (2001) Induction of a dopaminergic phenotype in cultured striatal neurons by bone morphogenetic proteins. Brain Res Dev Brain Res 130, 91-98, PubMed: 21441453 (Pubitemid 32830976)
129. Daadi, M.M. and Weiss, S. (1999) Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain. J Neurosci 19, 4484-4497, PubMed: 99274750 (Pubitemid 29241099)
130. Studer, L. et al. (2000) Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 20, 7377-7383, PubMed: 20482307
131. Sakurada, K. et al. (1999) Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126, 4017-4026, PubMed: 99387970 (Pubitemid 29481559)
132. W agner, J. et al. (1999) Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol 17, 653-659, PubMed: 99343368 (Pubitemid 29316143)
133. Storch, A. et al. (2001) Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 170, 317-325, PubMed: 21369608 (Pubitemid 32758685)
134. Suhonen, J.O. et al. (1996) Differentiation of adult hippocampus-derived progenitors into olfactory neurons in vivo. Nature 383, 624-627, PubMed: 97010477 (Pubitemid 26347584)
135. Fricker, R.A. et al. (1999) Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J Neurosci 19, 5990-6005, PubMed: 99337952 (Pubitemid 29327933)
136. Svendsen, C.N. et al. (1996) Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp Neurol 137, 376-388, PubMed: 96178061 (Pubitemid 26080334)
137. Svendsen, C.N. et al. (1997) Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol 148, 135-146, PubMed: 98063020 (Pubitemid 127445121)
138. Winkler, C. et al. (1998) Incorporation and glial differentiation of mouse EGF-responsive neural progenitor cells after transplantation into the embryonic rat brain. Mol Cell Neurosci 11, 99-116, PubMed: 98313401 (Pubitemid 28298382)
139. Shihabuddin, L.S. et al. (2000) Adult spinal cord stem cells generate neurons after transplantation in the adult dentate gyrus. J Neurosci 20, 8727-8735, PubMed: 20556632
140. Levesque, M.F. and Neuman, T. (2002) Autologous transplantation of human neural stem cells and differentiated dopaminergic neurons for Parkinson's disease: long term postoperative clinical and functional metabolic results. Exp Neurol 175, 71.